Development of Fast Dissolving Tablets of Losartan Potassium using Novel Co-processed Superdisintegrants

Losartan is used to treat high blood pressure (hypertension) and also used to lower the risk of stroke in certain people with heart disease. Therefore, the purpose of this study is to formulate mouth dissolving tablet of losartan potassium to improve its bioavailability, to attain fast onset of action and rise patient compliance. Owing to short bioavailability of 33% and to increase onset of action, fast dissolving tablets of Losartan Potassium were formulated using coprocessed superdisintegrants in order to improve the dissolution rate, in that way the bioavailability. The effect of concentration of the Croscarmellose sodium was studied by a set of three formulations (F1, F2, F3) with concentrations of 2%, 4% and 8% w/w respectively. Similarly, the impact of Sodium Starch Glycolate was studied by a set of three formulations (F4, F5 and F6) respectively. The formulation prepared with 8% w/w of superdisintegrant showed relatively rapid release of Losartan potassium when compared with other concentrations of Croscarmellose sodium and Sodium Starch Glycolate. The formulation prepared with Croscarmellose sodium had showed relatively fast release of Losartan Potassium when compared with Sodium Starch Glycolate. Three formulations (F7, F8 and F9) were prepared by including a combination of superdisintegrants (Co-processed Mixtures), Croscarmellose sodium and Sodium Starch Glycolate by direct compression method. Formulation containing Co-processed mixtures had less disintegration time as compared to the individual superdisintegrants. Subsequently, we can conclude that nature, concentration of the superdisintegrant in addition to combination of superdisintegrants (Co-processed) showed influence on the rate of dissolution.